Tumor necrosis factor inhibitor-associated dermatomyositis

Archives of Dermatology

Volumn 146, Issue 7, 2010, Pages 780-784

  Klein, Rachel ^a   Rosenbach, Misha ^a   Kim, Ellen J ^a   Kim, Brian ^a   Werth, Victoria P ^a,b   Dunham, Jonathan ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CLOBETASOL; CYCLOPHOSPHAMIDE; ETANERCEPT; HYDROXYCHLOROQUINE SULFATE; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; SUNSCREEN; TRIAMCINOLONE ACETONIDE; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FEMALE; FEVER; FIBROMYALGIA; HUMAN; HUMAN TISSUE; MALE; MUSCLE WEAKNESS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; PUNCH BIOPSY; RASH; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SYMPTOM; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; BLOOD; CHEMICALLY INDUCED; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED;

ADULT; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954820062     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.142     Document Type: Article

References (23)

1. Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. Best Pract Res Clin Rheumatol. 2004; 18(3):429-462.
2. Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol. 2008;59(5):872-880.
3. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666-R676.
4. Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 2006;55(6):982-984.
5. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22(5):847-861.
6. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007; 86(4):242-251.
7. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64(3):403-407.
8. Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33(9): 1802-1804. (Pubitemid 44373214)
9. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord. 1999;9(4):239-246.
10. Lundberg IE, Dastmalchi M. Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):799-822.
11. Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol. 2000;19(5):352-359.
12. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670-1677.
13. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48(7):716-720.
14. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5(4):285-294.
15. Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res. 1999;20(2):147-161.
16. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56(9):3112-3124.
17. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664-678.
18. Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. Apoptosis. 2000;5(5):443-449.
19. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285.
20. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-3140.
21. Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005;32(7):1232-1242. (Pubitemid 40995375)
22. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862-2869.
23. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47(6):1531-1534.